营收方面，合肥天曜2024年营收数千万元，预计今年实现翻倍增长。 据天眼查，庞昊为公司实际控制人，持股58.92%。庞昊目前担任公司董事长兼总经理。 瑞财经 王敏 8月29日，据36氪消息，半导体材料碲锌镉研发商合肥天曜新材料科技有限公司（以下简称"合肥天曜"）宣布完成数千万元A轮融资，由厚雪资 本领投，中芯聚源、国元基金跟投。 据悉，资金将主要用于产线扩大及产品研发，拓展海外市场及下游探测器集成业务。 合肥天曜成立于2020年4月，是一家专注于第三代战略性半导体晶体材料研发、生产及销售的技术企业，核心产品为碲锌镉（CdZnTe）衬底及器件，正在拓 展高端磷化铟(InP)、氮化铝(AlN)化合物半导体产品，致力于打破欧美日技术垄断，实现高端半导体材料国产自主可控。 ...

Core Insights - Hefei Tianyao New Materials Technology Co., Ltd. has recently completed a multi-million A round financing led by Huxue Capital, with participation from SMIC Juyuan and Guoyuan Fund, aimed at expanding production lines and product development, as well as exploring overseas markets and downstream detector integration business [1] Company Overview - Established in April 2020, Hefei Tianyao is located in Hefei Economic Development Zone and focuses on the research, production, and sales of third-generation strategic semiconductor crystal materials [1] - The company's core products include Cadmium Zinc Telluride (CdZnTe) substrates and devices, and it is expanding into high-end Indium Phosphide (InP) and Aluminum Nitride (AlN) compound semiconductor products [1] - Hefei Tianyao aims to break the technological monopoly held by Europe, the United States, and Japan, striving for self-controlled high-end semiconductor materials [1] Market Development - Photon CT using CdZnTe and Cadmium Telluride as detector materials has officially entered clinical use [1] - From the beginning of 2025 to the end of July, Siemens Medical has won bids from nearly 10 medical institutions, totaling 475 million yuan, with a single unit price of nearly 50 million yuan [1] - The photon counting spectral CT independently developed by United Imaging Healthcare has been installed in Zhongshan Hospital and Ruijin Hospital, initiating clinical testing and medical research [1] Strategic Positioning - The company recognizes the opportunity presented by the next generation of radiation detection technology and aims to become a core supplier in this wave [1] - Currently, Hefei Tianyao's CdZnTe products have achieved small batch supply in the medical field and have sent samples to several leading medical manufacturers, with expectations to enter a volume production phase next year [1]